Publications

by | March 27, 2012 | Uncategorized

Antitrust: Commission closes AstraZeneca and Nycomed investigations

On 1 March 2012, the European Commission has ceased its investigation of the pharmaceutical companies AstraZeneca and Nycomed. This research was based on a suspicion of individual or joint activity to delay the market entry of generic drugs.

This activity would have been contrary to EU antitrust rules that prohibit restrictive business practices and the abuse of a dominant market position, as per Articles 101 and 102 of the Lisbon Treaty.

The Commission has been investigating the pharmaceutical sector since 2008. Comprehensive inspection found some irregularities that prevented competition in this sector, particularly regarding the entry of generic drugs on the market.

Following this investigation, further inquiries have been launched to look at other pharmaceutical practices, including potential violations of EU competition rules and monitoring potentially problematic patent settlements.

—–
For further information

– European Commission DG Competition – overview of Antitrust legislation

EPHA related articles

– [->3255]
– [->2868]
– [->3037]
– [->5024]
– [->5014]
– [->5000]
– [->4984]
– [->4372]

Get the EPHA Newsletter

The best of our activities, right in your inbox!